Camargo Strengthens Research Team and Therapeutic Expertise
News Jul 24, 2014
Camargo Pharmaceutical Services has expanded its research team and therapeutic expertise with the addition of Dr. Wen-Yee Choi, Dr. Jillian Orans, Dr. Vien Lai and Kathryn Kemme.
Choi and Orans completed Camargo’s spring 2014 postdoctoral internship program and now join the company as research scientists. Choi specializes in cardiovascular medicine, including cardiac regeneration and bench-to-bedside research.
Her work on microRNA stem cell research is featured in numerous publications and presentations and is the subject of a pending patent, “Methods of Increasing Gene Expression Through RNA Protection.”
Orans has extensive experience in DNA mismatch repair in hereditary colon cancer, bacterial fitness and pathogenesis in infectious disease, and excels in using macromolecular crystallography to study the structural biology and biochemistry of proteins and nucleic acids.
Lai also joins Camargo as a research scientist with a focus on stem cell research and cardiovascular disease. His post-graduate training is focused on clinical medicine - specifically internal medicine, acute and emergency medicine, oncology and cardiovascular surgery.
As associate director of chemistry, manufacturing and control (CMC), Kemme provides direction and technical support for partnering contract manufacturing organizations. She has repeatedly conducted successful preapproval inspection readiness audits and gap analysis, and is proficient in project management, product transfer initiatives and scale-up.
“These individuals expand our capabilities and depth of skill in key therapeutic areas,” said Ken Phelps, president and CEO. “More so than ever, our team has the extensive knowledge and background needed to provide effective development solutions to our clients.”
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.